Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Ltd ADR (NQ: ZLAB )

18.97 -1.19 (-5.90%)
Streaming Delayed Price Updated: 2:54 PM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zai Lab Ltd ADR

< Previous 1 2 3 4 Next >
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
From Zai Lab Limited
Via Business Wire
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in May and June Investor Conferences
From Zai Lab Limited
Via Business Wire
Zai Lab Limited (NASDAQ:ZLAB) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 11/15/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Zai Lab Limited. 
Via SBWire
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
From Zai Lab Limited
Via Business Wire
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
From Zai Lab Limited
Via Business Wire
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
From Zai Lab Limited
Via Business Wire
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
From Zai Lab Limited
Via Business Wire
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
From Zai Lab Limited
Via Business Wire
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
From Zai Lab Limited
Via Business Wire
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in March Investor Conference
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
From Zai Lab Limited
Via Business Wire
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in January Investor Conference
From Zai Lab Limited
Via Business Wire
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Participation in November Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Participation in September Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Bowlero, and Chegg and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.